Our Pricing

Your Mounjaro And Pancreatitis Questions Answered

Published on: June 03, 2026

If you're researching mounjaro and pancreatitis uk safety information, you're taking the right precautions. Mounjaro (tirzepatide) is contraindicated in patients with a history of acute pancreatitis, and UK prescribers must carefully assess pancreatic risk factors before prescribing. At Cured Pharmacy, our clinical team evaluates every patient's medical history to ensure safe, appropriate treatment selection.

Understanding Mounjaro and Pancreatitis Risk

Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist that has been associated with rare cases of acute pancreatitis in clinical trials [1]. The SURPASS trial programme reported pancreatitis in approximately 0.2% of tirzepatide-treated patients compared to 0.1% in placebo groups, though the difference was not statistically significant [1].

The mechanism linking GLP-1 receptor agonists to pancreatitis remains unclear, but the MHRA advises that patients with a history of pancreatitis should not use Mounjaro [2]. UK prescribers are required to screen for pancreatic disease history during clinical assessment, and any patient reporting previous pancreatitis episodes will typically be deemed unsuitable for tirzepatide therapy.

Symptoms of acute pancreatitis include severe persistent abdominal pain, often radiating to the back, accompanied by nausea and vomiting. If you experience these symptoms whilst taking Mounjaro, you must stop the medication immediately and seek urgent medical attention [2].

Can You Take Mounjaro with a History of Pancreatitis?

No — Mounjaro is contraindicated in patients with a personal history of acute or chronic pancreatitis. This is an absolute contraindication listed in the UK Summary of Product Characteristics, meaning UK prescribers cannot legally prescribe tirzepatide to anyone who has experienced pancreatitis previously [2].

During your online consultation at Cured Pharmacy, you will be asked specifically about pancreatic disease history. Our UK prescribers, working under the clinical governance of superintendent pharmacist Tarun Kumar (GPhC 2233073), will decline Mounjaro prescriptions for any patient reporting previous pancreatitis, regardless of how long ago the episode occurred.

This precaution applies equally to all GLP-1 receptor agonists licensed in the UK, including semaglutide-based treatments. If you have pancreatitis history, alternative weight loss medications with different mechanisms of action may be more appropriate.

Risk Factors That May Exclude You from Mounjaro

Beyond previous pancreatitis, UK prescribers assess additional risk factors including gallstones (cholelithiasis), hypertriglyceridaemia above 500 mg/dL, and chronic alcohol consumption — all of which increase pancreatitis risk [3]. Patients with these conditions may be advised to pursue alternative weight management strategies or address underlying risk factors before considering GLP-1 therapy.

Mounjaro and Pancreatitis UK Clinical Evidence

The SURPASS-1 through SURPASS-5 trials enrolled over 6,000 patients across multiple tirzepatide doses. Pooled safety data showed 11 cases of acute pancreatitis among tirzepatide-treated patients (0.19%) versus 2 cases in comparator groups (0.11%) [1]. Whilst the absolute risk remains low, the MHRA determined the evidence sufficient to warrant a contraindication for patients with pancreatitis history.

Post-marketing surveillance data from the United States, where tirzepatide launched earlier, has not revealed pancreatitis rates exceeding those observed in clinical trials. However, real-world data collection continues, and UK healthcare professionals are encouraged to report any suspected pancreatitis cases via the Yellow Card scheme [2].

It's important to note that obesity itself is an independent risk factor for acute pancreatitis, with studies showing a 1.5 to 3-fold increased risk in individuals with BMI above 30 kg/m² [4]. This creates a complex clinical picture where the underlying condition being treated may itself contribute to pancreatic risk.

Recognising Pancreatitis Symptoms on Mounjaro

Patients prescribed Mounjaro should be counselled to recognise pancreatitis warning signs: severe upper abdominal pain that may radiate to the back, nausea, vomiting, and abdominal tenderness. These symptoms typically develop suddenly and persist, distinguishing them from the common gastrointestinal side effects (mild nausea, occasional vomiting) that often resolve within weeks of starting treatment [2].

Alternative Weight Loss Treatments for Patients with Pancreatitis History

If you have a history of pancreatitis, you are not suitable for any GLP-1 receptor agonist, including Mounjaro, Wegovy, or Saxenda. However, alternative prescription weight loss medications with different mechanisms may be appropriate, subject to clinical assessment by a UK prescriber.

Orlistat (available as generic formulations or branded Xenical) works by inhibiting pancreatic and gastric lipases, reducing dietary fat absorption by approximately 30% [5]. Crucially, orlistat does not stimulate the pancreas or affect GLP-1 pathways, making it a safer option for patients with pancreatic disease history. Clinical trials demonstrated average weight loss of 2.9 kg more than placebo over one year when combined with dietary modification [5].

Mysimba (naltrexone/bupropion combination) acts centrally on appetite regulation centres in the hypothalamus and does not directly affect pancreatic function [6]. This medication may be considered for patients with pancreatitis history, though individual assessment of contraindications (including seizure disorders and uncontrolled hypertension) is required.

Scientific References

1. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
3. Tenner, S., Baillie, J., DeWitt, J., & Vege, S. S. (2013). American College of Gastroenterology Guideline: Management of Acute Pancreatitis. American Journal of Gastroenterology, 108(9), 1400–1415. https://doi.org/10.1038/ajg.2013.218 [accessed 13 August 2026]
4. Sadr-Azodi, O., Orsini, N., Andrén-Sandberg, Å., & Wolk, A. (2013). Abdominal and Total Adiposity and the Risk of Acute Pancreatitis: A Population-Based Prospective Cohort Study. American Journal of Gastroenterology, 108(1), 133–139. https://doi.org/10.1038/ajg.2012.381 [accessed 13 August 2026]
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. Greenway, F. L., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. If you experience symptoms of pancreatitis (severe abdominal pain, nausea, vomiting), stop your medication and seek urgent medical attention.